Abstract
In the last decades the epidermal growth factor receptor (EGFR), which is frequently expressed in a variety of epithelial tumors, has been a major target of molecular anticancer therapy.
Keywords: EGFR, Monoclonal antibody, Tyrosine kinase inhibitor, resistance
Current Cancer Therapy Reviews
Title: Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors
Volume: 3 Issue: 4
Author(s): Floriana Morgillo, Giampaolo Tortora and Fortunato Ciardiello
Affiliation:
Keywords: EGFR, Monoclonal antibody, Tyrosine kinase inhibitor, resistance
Abstract: In the last decades the epidermal growth factor receptor (EGFR), which is frequently expressed in a variety of epithelial tumors, has been a major target of molecular anticancer therapy.
Export Options
About this article
Cite this article as:
Morgillo Floriana, Tortora Giampaolo and Ciardiello Fortunato, Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors, Current Cancer Therapy Reviews 2007; 3 (4) . https://dx.doi.org/10.2174/157339407782496988
DOI https://dx.doi.org/10.2174/157339407782496988 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypericin and its Derivatives Act as Radiosensitizing Agents That Can Inhibit Tumor Initiating Cell Viability
Clinical Cancer Drugs Calcium Channels and Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery Design of Magnetic Nanoparticles-Assisted Drug Delivery System
Current Pharmaceutical Design Cellular Immunotherapy for Neuroblastoma: A Review of Current Vaccine and Adoptive T Cell Therapeutics
Current Pharmaceutical Design TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Current Phthalocyanines Delivery Systems in Photodynamic Therapy: An Updated Review
Current Medicinal Chemistry Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design Recent Progress in Phosphoinositide 3-Kinases: Oncogenic Properties and Prognostic and Therapeutic Implications
Current Protein & Peptide Science DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design Biology and Clinical Relevance of Mannose-Binding Lectin
Drug Design Reviews - Online (Discontinued) Antibody Targeting of TGF-β in Cancer Patients
Current Pharmaceutical Biotechnology Spectroscopic and Chromatographic Characterization of Crude Natural Shilajit from Himachal Pradesh, India
The Natural Products Journal Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Small Molecule Integrin Antagonists in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Raman Spectroscopy and Imaging: Promising Optical Diagnostic Tools in Pediatrics
Current Medicinal Chemistry Human- and Virus-Encoded microRNAs as Potential Targets of Antiviral Therapy
Mini-Reviews in Medicinal Chemistry Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells
Current Pharmaceutical Design Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins
Anti-Cancer Agents in Medicinal Chemistry Serotonergic and Cholinergic Strategies as Potential Targets for the Treatment of Schizophrenia
Current Pharmaceutical Design